Original articles
Fangfang Li, Zongliang Liu, Heyuan Sun, Chunmei Li, Wenyan Wang, Liang Ye, Chunhong Yan, Jingwei Tian, Hongbo Wang. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo[J]. Acta Pharmaceutica Sinica B, 2020, 10(2): 289-300

PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
Fangfang Lia, Zongliang Liua, Heyuan Suna, Chunmei Lia, Wenyan Wanga, Liang Yeb, Chunhong Yana,c, Jingwei Tiana, Hongbo Wanga
a School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China;
b Department of Clinical Medicine, Binzhou Medical College, Yantai 256603, China cGRU Cancer Center, Augusta University, Augusta, GA 30912, USA
Abstract:
Gliomas are the most common primary intracranial neoplasms among all brain malignancies, and the microtubule affinity regulating kinases (MARKs) have become potential drug targets for glioma. Here, we report a novel dual small-molecule inhibitor of MARK3 and MARK4, designated as PCC0208017. In vitro, PCC0208017 strongly inhibited kinase activity against MARK3 and MARK4, and strongly reduced proliferation in three glioma cell lines. This compound attenuated glioma cell migration, glioma cell invasion, and angiogenesis. Molecular mechanism studies revealed that PCC0208017 decreased the phosphorylation of Tau, disrupted microtubule dynamics, and induced a G2/M phase cell cycle arrest. In an in vivo glioma model, PCC0208017 showed robust anti-tumor activity, bloodebrain barrier permeability, and a good oral pharmacokinetic profile. Molecular docking studies showed that PCC0208017 exhibited high binding affinity to MARK3 and MARK4. Taken together, our study describes for the first time that PCC0208017, a novel MARK3/MARK4 inhibitor, might be a promising lead compound for treatment of glioma.
Key words:    Glioma    PCC0208017    MARK3    MARK4    Molecular docking   
Received: 2019-06-19     Revised: 2019-08-01
DOI: 10.1016/j.apsb.2019.09.004
Funds: We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. This work was partially supported by National Science Foundation of China (NSFC, 81728020), Key Research Project of Shandong Province (2017GSF18177, China), Natural Science Foundation of Shandong Province (ZR2018LH025, China), The Science and Technology Support Program for Youth Innovation in Universities of Shandong (2019KJM009), Key Research Project of Yantai (2019XDHZ102, China) and Taishan Scholar Project.
Corresponding author: Jingwei Tian, Hongbo Wang     Email:YTUpharmlab@163.com;hongbowangyt@gmail.com
Author description:
Service
PDF(KB) Free
Print
0
Authors
Fangfang Li
Zongliang Liu
Heyuan Sun
Chunmei Li
Wenyan Wang
Liang Ye
Chunhong Yan
Jingwei Tian
Hongbo Wang

References:
1. Daniel DA, Karim RF, William C, Beata D, Selby GC, H Gordon D, et al. Prognostic factors and survival in low grade gliomas of the spinal cord:a population-based analysis from 2006 to 2012. J Clin Neurosci 2018;61:14-21.
2. Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res 2015;163:1-14.
3. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 1997;89:297-308.
4. Trinczek B, Brajenovic M, Ebneth A, Drewes G. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. J Biol Chem 2004;279:5915-23.
5. Timm T, Marx A, Panneerselvam S, Mandelkow E, Mandelkow EM. Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. BMC Neurosci 2008;9:S9.
6. Bright NJ, Thornton C, Carling D. The regulation and function of mammalian AMPK-related kinases. Acta Physiol 2009;196:15-26.
7. Marx A, Nugoor C, Panneerselvam S, Mandelkow E. Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases. FASEB J 2010;24:1637-48.
8. Natalia MA, Alejandro GT, Virginia TJ, Alvarez-Salas LM. MARK1 is a novel target for miR-125a-5p:implications for cell migration in cervical tumor cells. MicroRNA 2018;7:54-61.
9. Hubaux R, Thu KL, Vucic EA, Pikor LA, Kung SH, Martinez VD, et al. Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer. Int J Cancer 2015;137:2072-82.
10. Kato T, Satoh S, Okabe H, Kitahara O, Ono K, Kihara C, et al. Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis. Neoplasia 2001; 3:4-9.
11. Magnani I, Novielli C, Fontana L, Tabano S, Rovina D, Moroni RF, et al. Differential signature of the centrosomal MARK4 isoforms in glioma. Anal Cell Pathol 2011;34:319-38.
12. Beghini A, Magnani I, Roversi G, Piepoli T, Terlizzi SD, Moroni RF, et al. The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. Oncogene 2003;22:2581-91.
13. Jenardhanan P, Mannu J, Mathur PP. The structural analysis of MARK4 and the exploration of specific inhibitors for the MARK family:a computational approach to obstruct the role of MARK4 in prostate cancer progression. Mol Biosyst 2014;10:1845-68.
14. Pardo OE, Castellano L, Munro CE, Hu Y, Mauri F, Krell J, et al. miR-515-5p controls cancer cell migration through MARK4 regulation. EMBO Rep 2016;17:570-84.
15. Heidary AE, Shiban A, Song S, Attisano L. MARK4 inhibits hippo signaling to promote proliferation and migration of breast cancer cells. EMBO Rep 2017;18:420-36.
16. Khan P, Rahman S, Queen A, Manzoor S, Naz F, Hasan GM, et al. Elucidation of dietary polyphenolics as potential inhibitor of microtubule affinity regulating kinase 4:in silico and in vitro studies. Sci Rep 2017;7:9470.
17. Aneja B, Khan NS, Khan P, Queen A, Hussain A, Rehman MT, et al. Design and development of isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis. Eur J Med Chem 2019;163:840-52.
18. Parveen I, Khan P, Ali S, Hassan MI, Ahmed N. Synthesis, molecular docking and inhibition studies of novel 3-n-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors. Eur J Med Chem 2018;159:166-77.
19. Ma YT, Yang Y, Cai P, Sun DY, Sánchez-Murcia PA, Zhang XY, et al. A series of enthalpically optimized docetaxel analogues exhibiting enhanced antitumor activity and water solubility. J Nat Prod 2018;81:524-33.
20. Li DJ, Tong J, Zeng FY, Guo M, Li YH, Wang H, et al. Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3. Br J Pharmacol 2019;176:4388-401.
21. Lv G, Sun D, Zhang J, Xie X, Wu X, Fang W, et al. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo. Acta Pharm Sin B 2017;7:52-8.
22. Wang HB, Ma XJ, Ren SM, John K, Buolamwini JK, Yan C. A smallmolecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 2011;10:69-79.
23. Ding MM, Wang HB, Qu CR, Xu FH, Zhu YM, Lv GY, et al. Pyrazolo[1,5-a] pyrimidine TRPC6 antagonists for the treatment of gastric cancer. Cancer Lett 2018;432:47-55.
24. Yang YT, Guan DK, Lei L, Lu J, Liu JQ, Yang GQ, et al. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. Toxicol Appl Pharmaco 2018;341:98-105.
25. Zhang D, Xu Q, Wang N, Yang YT, Liu JQ, Yu GH, et al. A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth. Int J Nanomedicine 2018;13:4549-61.
26. Sun SY, Du GY, Xue J, Ma JB, Ge MM, Wang HB, et al. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models. Int J Immunopathol Pharmacol 2018;32:1-14.
27. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol 2016;18:1-75.
28. Wang JL, Ma YF, Cooper MK. Cancer stem cells in glioma:challenges and opportunities. Transl Cancer Res 2013;2:429-41.
29. Katsetos CD, Reginato MJ, Baas PW, D'Agostino L, Legido A, Tuszyn SJ, et al. Emerging microtubule targets in glioma therapy. Semin Pediatr Neurol 2015;22:49-72.
30. Josiana GA, Ricardo PR, Leonardo BF, Carlos HT. Structure-based drug design of novel MARK-3 inhibitors in cancer. Curr Bioact Comp 2014;10:131-8.
31. Jonathan RA, Josiana GA, Joao GP, Carlton AT, Carlos HP. Ligandbased drug design of novel MARK-3 inhibitors in cancer. Curr Bioact Comp 2014;10:112-23.
32. Trinczek B, Ebneth A, Mandelkow EM, Mandelkow E. Tau regulates the attachment/detachment but not the speed of motors in microtubuledependent transport of single vesicles and organelles. J Cell Sci 1999; 112:2355-67.
33. Preuss U, Mandelkow EM. Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer's disease. Eur J Cell Biol 1998;76:176-84.
34. Rovina D, Fontana L, Monti L, Novielli C, Panini N, Sirchia SM, et al. Microtubule-associated protein/microtubule affinity-regulating kinase 4(MARK4) plays a role in cell cycle progression and cytoskeletal dynamics. Eur J Cell Biol 2014;93:355-65.
35. Abbott NJ. Bloodebrain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013;36:437-49.